GAO participation in FDA foreign plant inspections under consideration.
This article was originally published in The Tan Sheet
Executive Summary
GAO FOREIGN INSPECTION PARTICIPATION UNDER DISCUSSION WITH FDA in light of a recent General Accounting Office report on "Improvements Needed in the Foreign Drug Inspection Program," presented to House Commerce/Oversight Subcommittee Chairman Joe Barton (R-Tex.) in March and released April 24. The subcommittee tentatively had planned a hearing on the report for April but has postponed the session pending further research, including examination of possible GAO participation in foreign drug manufacturing plant inspections.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning